Bausch Health Companies adjusts debt profile, shares react to refinancing step
25.06.2026 - 16:16:19 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 16:15.
Bausch Health Companies Inc. (CA0717341071) remains under scrutiny as the healthcare group continues to work on its heavy debt load in the wake of prior refinancing steps reported in recent months. The stock trades on the New York Stock Exchange alongside peers such as Pfizer and AbbVie.
Debt and refinancing context
Bausch Health Companies carries a substantial debt burden following its legacy structure and has been refinancing tranches across recent quarters, as highlighted in prior company filings with the U.S. Securities and Exchange Commission. The company has used bond issuance and term loans to push out maturities and adjust interest costs. Company news and filings on the Bausch Health debt structure
The healthcare group operates in prescription pharmaceuticals and medical devices, and its high leverage has repeatedly attracted attention from analysts covering specialty pharma and generics. While no major new refinancing tranche has been announced today, recent quarters have seen the group opportunistically tap credit markets when conditions permitted. SEC filings with detailed debt and refinancing information
Analysts view and sector comparison
Analysts regularly compare Bausch Health with large-cap peers such as Pfizer and AbbVie in terms of balance-sheet resilience and cash generation, but the company sits in a different risk bracket due to its elevated leverage and past restructuring issues. Some houses flag its debt as a key valuation driver and monitor progress on deleveraging and EBITDA trends. MarketScreener analyst and market commentary on Bausch Health
Compared with broader sector names in the S&P 500 healthcare segment, Bausch Health shares often show higher volatility around earnings and capital-structure updates. This reflects the sensitivity of its equity to small changes in guidance, free cash flow and refinancing costs, according to several market commentaries. Reuters coverage of Bausch Health and its sector positioning
Further news and analysis on Bausch Health Companies shares
Investors can follow additional updates on the Bausch Health Companies stock and its refinancing path via our topic page and the firm's investor relations portal.
What the company sells
Bausch Health Companies generates revenue through prescription pharmaceuticals, branded generics and medical devices, including eye-health products under the Bausch + Lomb label. Its portfolio spans dermatology, neurology and gastrointestinal treatments, giving it a diversified base of healthcare cash flows.
Where the stock trades today
As of 2026-06-25, 14:00, Bausch Health Companies shares trade at approximately 7.50 U.S. dollars on the New York Stock Exchange, reflecting the market's cautious stance toward the group's leveraged balance sheet and refinancing trajectory.
Bausch Health Companies at a glance
- Company: Bausch Health Companies Inc.
- ISIN: CA0717341071
- WKN: A2PXV4
- Ticker: BHC
- Trading venue: NYSE
- Price (as of 2026-06-25, 14:00): 7.50 USD
- Market cap: roughly 2.7 billion USD (as of 2026-06-25)
- Sector / industry: Health Care - Pharmaceuticals and Medical Devices
- Index membership: not part of the S&P 500, trades in the broader U.S. healthcare universe
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
